Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Breast Cancer


 CMFVP                                                  breast(23)
 _________________________________________________________________
  cytoxan......... 400 mg/sqm IV day 1.
  methotrexate.... 30 mg/sqm IV days 1 and 8.
  fluorouracil.... 400 mg/sqm IV days 1 and 8.
  vincristine..... 1 mg IV days 1 and 8.
  prednisone...... 20 mg orally four times daily on days 1 to 7.
  FREQUENCY....... Repeat cycle every 28 days.

  reference...
    Smalley RV.  Carpenter J.  Bartolucci A.  Vogel C.  Krauss S. 
    A comparison of cyclophosphamide, adriamycin, 5-fluorouracil 
    (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, 
    vincristine, prednisone (CMFVP) in patients with metastatic 
    breast cancer: a Southeastern Cancer Study Group project. 
    Cancer.  40(2):625-32, 1977 Aug. 
  abstract...
    In an ongoing prospective randomized study, 113 evaluable 
    patients have received either a three-drug combination that 
    included cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) 
    or a five-drug combination including cyclophosphamide, 
    methotrexate, 5-fluorouracil, vincristine and prednisone 
    (CMFVP) given intermittently 1 week out of 4. Responses (64%), 
    median duration of response (32 weeks), and median duration of 
    disease control (32 weeks) achieved with CAF were superior to 
    those achieved with CMFVP (37%, 22 weeks, 17 weeks, 
    respectively). Morbidity secondary to CAF was significant, 
    with nausea and vomiting, malaise, total alopecia, and 
    granulocytopenia being the main features. 
advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application



 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.